Health Discovery Corp. advanced stock charts by Barron's. View HDVY historical stock data and compare to other stocks, and exchanges.
Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback